- Q1 2024 Arbutus Biopharma Corp Earnings Call TranscriptMay 02, 2024$2.68 (-0.37%)Earnings
- Q4 2023 Arbutus Biopharma Corp Earnings Call TranscriptFeb 29, 2024$2.8 (-2.78%)Earnings
- Q3 2023 Arbutus Biopharma Corp Earnings Call TranscriptNov 07, 2023$1.85 (-1.60%)Earnings
- Q2 2023 Arbutus Biopharma Corp Earnings Call TranscriptAug 03, 2023$2.06 (-0.96%)Earnings
- Arbutus Biopharma Corp at JMP Securities Life Sciences Conference TranscriptMay 16, 2023
- Q1 2023 Arbutus Biopharma Corp Earnings Call TranscriptMay 04, 2023$2.55 (+1.59%)Earnings
- Q4 2022 Arbutus Biopharma Corp Earnings Call TranscriptMar 02, 2023$2.81Earnings
- Q3 2022 Arbutus Biopharma Corp Earnings Call TranscriptNov 09, 2022$2.44 (-0.81%)Earnings
- Arbutus Biopharma Corp AASLD Call TranscriptNov 04, 2022
- Q2 2022 Arbutus Biopharma Corp Earnings Call TranscriptAug 04, 2022$2.54 (+3.25%)Earnings
- Arbutus Biopharma Corp to Discuss New Data at EASL ILC 2022 TranscriptJun 27, 2022
- Arbutus Biopharma Corp at JMP Securities Life Sciences Conference (Virtual) TranscriptJun 15, 2022
- Q1 2022 Arbutus Biopharma Corp Earnings Call TranscriptMay 05, 2022$2.55 (+2.41%)Earnings
- Q4 2021 Arbutus Biopharma Corp Earnings Call TranscriptMar 03, 2022$2.95 (-4.53%)Earnings
- Q3 2021 Arbutus Biopharma Corp Earnings Call TranscriptNov 04, 2021$3.88 (+0.78%)Earnings
- Arbutus Biopharma Corp at Chardan Genetic Medicines Conference (Virtual) TranscriptOct 05, 2021
- Arbutus Biopharma Corp at Cantor Fitzgerald Global Healthcare Conference (Virtual) TranscriptSep 30, 2021
- Q2 2021 Arbutus Biopharma Corp Earnings Call TranscriptAug 05, 2021$3.04 (+10.14%)Earnings
- Arbutus Biopharma Corp to Discuss the New Data Being Presented at EASL - Conference Call TranscriptJun 28, 2021
- Arbutus Biopharma Corp at JMP Securities Life Sciences Virtual Conference TranscriptJun 17, 2021
- Arbutus Biopharma Corp Annual Shareholders Meeting TranscriptMay 26, 2021
- Q1 2021 Arbutus Biopharma Corp Earnings Call TranscriptMay 05, 2021$2.96 (-11.11%)Earnings
- Q4 2020 Arbutus Biopharma Corp Earnings Call TranscriptMar 04, 2021$3.14 (-13.74%)Earnings
- Arbutus Biopharma Corp to Provide an AB-729 Clinical Update - Conference Call TranscriptNov 16, 2020
- Q3 2020 Arbutus Biopharma Corp Earnings Call TranscriptNov 05, 2020$2.87 (-6.21%)Earnings
- Q2 2020 Arbutus Biopharma Corp Earnings Call TranscriptAug 07, 2020$3.8 (-13.04%)Earnings
- Arbutus Biopharma Corp Annual Shareholders Meeting TranscriptMay 28, 2020
- Arbutus Biopharma Corp at UBS Global Healthcare Conference (Virtual) TranscriptMay 19, 2020
- Arbutus Biopharma Corp AB-729 Clinical Update Conference Call TranscriptMay 18, 2020
- Q1 2020 Arbutus Biopharma Corp Earnings Call TranscriptMay 11, 2020$1.44 (+6.67%)Earnings
- Arbutus Biopharma Corp to Discuss the Preliminary Phase 1a/1b Clinical Trial Results for AB-729 Conference Call TranscriptMar 26, 2020
- Q4 2019 Arbutus Biopharma Corp Earnings Call TranscriptMar 05, 2020$3 (-0.99%)Earnings
- Q3 2019 Arbutus Biopharma Corp Earnings Call TranscriptNov 06, 2019$1.45 (-2.68%)Earnings
- Q2 2019 Arbutus Biopharma Corp Earnings Call TranscriptAug 05, 2019$1.6 (-1.84%)Earnings
- Arbutus Biopharma Corp to Discuss Preliminary Phase 1a/1b Clinical Trial Results for AB-506 - Call TranscriptJul 15, 2019
- Arbutus Biopharma Corp at JMP Securities Life Science Conference TranscriptJun 20, 2019
- Arbutus Biopharma Corp at UBS Global Healthcare Conference TranscriptMay 20, 2019
- Q1 2019 Arbutus Biopharma Corp Earnings Call TranscriptMay 06, 2019$2.63 (+0.77%)Earnings
- Q4 2018 Arbutus Biopharma Corp Earnings Call TranscriptMar 07, 2019$4.02Earnings
Arbutus Biopharma Corp at UBS Global Healthcare Conference Transcript
Good afternoon, everybody. Thank you for coming to the 2019 UBS Global Healthcare Conference. My name is [Hannah], and I'll be your host for this session. Our next speaker is Dr. Mark Murray, President and CEO of Arbutus Biopharma. There'll be a breakout session held in Uris shortly after this presentation. Thank you.
Thank you. Good afternoon, and thank you all for coming today to hear about Arbutus Biopharma. Arbutus is a company that is committed to the development of an effective combination regimen to achieve an HBV cure. We are now more convinced than ever that this combination approach is correct. Thank you. Okay. Arbutus is a publicly traded company, and I will be making forward-looking statements this afternoon.
Arbutus, as I said, has a singular therapeutic focus, the cure of chronic hepatitis B. Chronic hepatitis B is a very large, unmet global need. It is estimated that there are over 250 million infected individuals worldwide. To address this
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)